Evidence map›Paper›PMID 39727149›Full record

ArticleCancer medicine2025

Activin A promoted the anti-tumor effect of ActRIIA

Liangchang Hu, Yu Zhao, Xuguang Zhang, Chunhui Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Liangchang HuDepartment of Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Yu ZhaoSchool of Medical Laboratory, Shandong Second Medical University, Weifang, China.
Xuguang ZhangDepartment of Clinical Laboratory, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Chunhui MaDepartment of Clinical Laboratory, Affiliated Hospital of Shandong Second Medical University, Weifang, China.ORCID https://orcid.org/0000-0001-7133-3644

Funding

This research is supported by the Natural Science Foundation of Shandong Province of China (ZR2021QH311).
6 · The paper itself

Abstract

backgroundActivin A, a noteworthy member of the TGF-β superfamily. Activin A can regulate the biological functions of various immune cells, such as macrophages, neutrophils, NK cells, etc. The purpose of this study is to investigate the regulatory effect and related mechanisms of activin A on CD8

methodsThis study established a mouse subcutaneous transplantation model of hepatoma to explore whether activin A has a regulatory effect of CD8

resultsWe discovered that CD8

conclusionsThis study demonstrated that low-dose activin A enhanced the anti-tumor effect of CD8

Indexed as

ActivinsCarcinoma, HepatocellularCD8-Positive T-LymphocytesLiver NeoplasmsActivin Receptors, Type IIAnimalsCell Line, TumorCell ProliferationDisease Models, AnimalMaleMiceactivin AActivin Receptors, Type IIActivinsactivin ACD8+ T cellshepatomaimmune regulationtumor immunity

Identifiers

PMID39727149
PMCPMC11672029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.